Anatara Lifesciences gets good news on GaRP supplement

Anatara Lifesciences (ASX:ANR) has released encouraging pre-clinical trial data of its Gastrointestinal ReProgramming (GaRP) dietary supplement which targets diarrhoea. The company is now targeting the second half of this year for human trials of GaRP which treats underlying causes such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). “Anatara believes its GaRP dietary…

Admedus receives approval for human heart valve implants

Heart surgery product developer Admedus (ASX: AHZ) has received approvals for its first in-human trial at Leuven University Hospital of the company’s proprietary ADAPT single-piece 3D aortic valve. The Belgian surgeon Professor Bart Meuris will conduct the trial of 15 patients who will be followed up six month after receiving the ADAPT implant. Results of…

Lepidico makes progress in lithium chemicals

Lithium chemicals company Lepidico (ASX: LPD) has successfully produced lithium hydroxide monohydrate (LOH) suitable for battery production from its Perth pilot plant operation (pictured). The results were achieved in a batch trial of Lepidico’s proprietary LOH-Max process, with impurity levels comparable to lithium produced using conventional methods. Purities of greater than 56.5 per cent LOH…

Supply deal brings Australian-made, graphene-enhanced footwear closer to reality

Two WA companies, First Graphene (ASX: FGR) and boot-maker Steel Blue, announced a 24-month supply agreement, with graphene additives to enhance an upcoming release of safety boots.   This nanomaterial will be incorporated in boot components, including a thermoplastic polyurethane (TPU) sole. Graphene is a single layer of hexagonally-arranged carbon atoms, first successfully created in…